厄洛替尼治疗不同病理类型晚期非小细胞肺癌疗效观察

Observation on efficacy of erlotinib in patients with advanced non-small cell lung cancer of differential pathological types

目的探讨厄洛替尼治疗不同病理类型晚期非小细胞肺癌的疗效。方法对接受过1个周期以上含铂化疗方案失败的晚期非小细胞肺癌患者48例,每天口服150mg厄洛替尼直至疾病进展,观察厄洛替尼治疗不同病理类型晚期非小细胞肺癌的疗效、生存时间。采用Kaplan-Meier法分析比较两组间生存率差异。结果腺癌组36例,有效率为36%(13/36),非腺癌组12例,有效率为25%(3/12),腺癌组与非腺癌组有效率差异无显著性。采用Kaplan-Meier法比较不同病理类型组间的无进展时间、总生存时间差异。腺癌组中位无进展时间为6个月,非腺癌组中位无进展时间为3个月,两组之间差异无显著性。腺癌组中位生存时间为14个月,非腺癌组中位生存时间为4个月,两组之间差异有显著性。结论对于不同病理类型晚期非小细胞肺癌患者,厄洛替尼均有效,且腺癌患者生存期较非腺癌组长。

Objective To explore the efficacies of erlotinib in patients with advanced non-small cell lung cancer of different pathological types. Methods Patients with non-small cell lung cancer who had been previously treated with at least one course of platinum-based chemotherapy were administered with 150 mg oral doses of erlotinib once daily until disease progression. Response rate, progression free survival, overall survival were analyzed in the groups with differential pathological type. Kaplan-Meier method was used to analyze the survival rate. Results The response rate was 36 percent in the adenocarcinoma group （13/36） and 25 percent in the non-adenocarcinoma group （3/12） ; the median progression-free survivals were 6 months and 3 months respectively. The median overall survivals were 14 months and 4 months. Conclusions Erlotinib was an effective drug for patients with advanced non-small cell lung cancer of differential pathological types and was better on overall survival for the patient with adenocarcinoma than other pathological types.